Senators in the US Congress have written to the US Food and Drug Administration seeking changes to official guidance, with the aim of expediting the release of new biosimilar insulin products.
The letter comes shortly after Eli Lilly (NYSE: LLY) announced it will introduce a steeply discounted version of its own Humalog (insulin lispro) in the USA.
The FDA is due to begin work in March 2020 transitioning certain approved products to be classed as biologics. This will include insulin and human growth hormone.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze